Company Overview: IRWD

Upcoming Projects (IRWD)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (IRWD)

Don’t see a project related to the company you care about? Create your own!

Upcoming & Overdue Catalysts (IRWD)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (IRWD)

Ironwood (IRWD) Expects to Initiate Phase 3 Trial Evaluating CR1 in IBS-C in the Second Half of 2017
Ticker: IRWD
Occurred on: Jul 16, 2018
Ardelyx, Inc. Expected to Release Clinical Data by Late 2017 from T3MPO-2 Trial with Tenapanor in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
Tickers: ARDX, SGYP, IRWD
Occurred on: Oct 16, 2017
Ironwood Pharmaceuticals (IRWD) Announces FDA Approval of DUZALLO (lesinurad and allopurinol) for the Treatment of Hyperuricemia in Patients with Uncontrolled Gout
Ticker: IRWD
Occurred on: Aug 21, 2017
Ironwood (IRWD) Expects Phase 2b Data in Mid-2017 Evaluating IW-3718 for Uncontrolled GERD
Ticker: IRWD
Occurred on: Jul 20, 2017
Ardelyx, Inc. Expected to Release Clinical Data by Mid-2017 from T3MPO-1 Trial with Tenapanor in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
Tickers: ARDX, SGYP, IRWD
Occurred on: May 12, 2017
Astellas (ALPMY) and Ironwood (IRWD) Expect to Launch Linzess in Japan for the Treatment of Adults with IBS-C in the First Half of 2017
Tickers: IRWD, ALPMY
Occurred on: May 08, 2017
PDUFA Date in Early 2017 for Allergan (AGN) and Ironwood's (IRWD) Supplemental Application for 72 mcg Linzess in Treatment of IBS-C and Chronic Idiopathic Constipation
Tickers: IRWD, AGN
Occurred on: Jan 26, 2017
Ironwood and Allergan Announce Supplemental New Drug Application for 72 mcg Linaclotide in Chronic Idiopathic Constipation Has Been Accepted for FDA Review
Tickers: IRWD, AGN
Occurred on: Jun 09, 2016
The First Phase 3 trial for Plecanatide in IBS-C read out
Tickers: SGYP, PFE, AGN, VRX, IRWD
Occurred on: May 22, 2016
Ironwood Pharmaceuticals Reports Top-Line Data from Exploratory Phase IIa Study of IW-9179 in Diabetic Gastroparesis; Ironwood intends to discontinue development of IW-9179 for gastroparesis
Ticker: IRWD
Occurred on: Apr 05, 2016

Strategic Initiatives (IRWD)

Don’t see a strategic initiative related to the company you care about? Create your own!

IRWD Overview